Lupin on Friday launched NaMuscla, an orphan drug used for the treatment of myotonia in adults, in Germany and the United Kingdom. An orphan drug is a synthetic pharmaceutical, which remains commercially undeveloped. The launch of the drug in Germany (by its subsidiary Hormosan Pharma GmbH) and in the UK (Lupin Healthcare (UK) Ltd) follows the European Commission’s approval of the product in December 2018. Shareholders will monitor the development.